EBD RCT Trial in Living Donor Liver Transplantation

Sponsor
Seoul National University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04622540
Collaborator
(none)
124
1
2
70.7
1.8

Study Details

Study Description

Brief Summary

This study was designed to demonstrate incidence of biliary complication rates after living donor liver transplantation according to the implantation of external biliary drainage throug duct-to-duct anastomosis site.

Condition or Disease Intervention/Treatment Phase
  • Procedure: External biliary drainage
N/A

Detailed Description

Biliary complication is the most common complications after liver transplantation, and it happens more often after living donor liver transplantation (LDLT) than deceased donor liver transplantation.

Many transplant centers adopted their own methods to improve biliary complications after LDLT. One suggested method is the application of external biliary drainage (EBD).

A prospective study was planned to demonstrate effect of EBD on biliary complication after LDLT. Patients who underwent LDLT with duct-to-duct anastomosis will be randomly assinged to application of EBD or conventional duct-to-duct anastomosis without EBD according to a computer generated randomization sequence and allocated in a 1:1 ratio to one of two groups.

Primary outcome is biliary complication incidence 1 year after LDLT.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
124 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Prospective Randomized Controlled Trial for Application of External Biliary Drainage in Living Donor Liver Transplantation
Actual Study Start Date :
Dec 9, 2020
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental group

Application of external biliary drainage

Procedure: External biliary drainage
Application of external biliary drainage through duct-to-duct anastomosis

No Intervention: Control group

Conventional duct-to-duct anastomosis (with or without internal stent)

Outcome Measures

Primary Outcome Measures

  1. Incidence of biliary complication within 1 year after LDLT [1 year]

    Biliary stricture/leakage

Secondary Outcome Measures

  1. Incidence of biliary complication within 3 year after LDLT [3 year]

    Biliary stricture/leakage

  2. Complication associated with external biliary drainage [3 year]

    Dislocation, retraction, reposition, leakage through tube site, hemorrhage

  3. Graft survival [3 year]

    Survival of liver graft

  4. Patient survival [3 year]

    Patient survival after LDLT

  5. Patient-reported outcome [3 year]

    Questionnaire survey

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Living donor liver transplantation

  • Adult patient (>=18 years old)

  • Patients who are available for at least 3 year follow-up after LDLT

Exclusion Criteria:
  • Patients requring hepaticojejunostomy due to anatomical factor or underlying disease

  • Re-transplantation

  • Multiorgan transplantation

  • Emergency transplantation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Seoul National University Hospital Seoul Korea, Republic of

Sponsors and Collaborators

  • Seoul National University Hospital

Investigators

  • Study Chair: Suk Kyun Hong, MD, Seoul National University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Suk Kyun Hong, Clinical Assistant Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT04622540
Other Study ID Numbers:
  • SNUHLT_EBD
First Posted:
Nov 10, 2020
Last Update Posted:
May 12, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 12, 2022